Education
About Us
Working with TipRanks
Follow Us
RUA Life Sciences (GB:RUA)
LSE:RUA
RUA Stock Chart & Stats
14.00p
-0.50p(-3.85%)
At close: 4:00 PM EST
14.00p
-0.50p(-3.85%)
Day’s Range― - ―
52-Week Range10.42p - 16.80p
Previous CloseN/A
Volume378.53K
Average Volume (3M)148.53K
Market Cap
£9.00M
Enterprise Value7.10M
Total Cash (Recent Filing)£3.57M
Total Debt (Recent Filing)£1.03M
Price to Earnings (P/E)43.9
Beta0.26
Next Earnings
Jul 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio-75.00
Price to Book (P/B)1.03
Price to Sales (P/S)1.82
P/FCF Ratio-26.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginSustained double-digit revenue growth (40.81% last year) combined with a 77.12% gross margin indicates strong product demand and efficient cost of goods in biomaterials. This supports reinvestment in R&D and capacity expansion, reinforcing durable top-line momentum if operating costs are later controlled.
Conservative Capital StructureA low debt-to-equity ratio (0.14) and a strong equity ratio provide financial flexibility to fund clinical development, scale manufacturing, and endure regulatory timelines typical in medical devices. Conservative leverage lowers refinancing risk and supports strategic investments without stressing solvency.
Strategic Diversification & M&AReported diversification and strategic acquisitions represent structural moves to broaden product offerings and accelerate commercialization. Over several quarters this can deepen market position, create cross-selling opportunities, and improve margin mix as higher-value products scale within the biomaterials ecosystem.
Bears Say
Weak Operating Cash FlowNegative operating cash flow and declining free cash flow signal the company is not yet self-funding its operations. Persistent cash burn forces reliance on external financing or equity raises, which can dilute holders or limit the firm's ability to invest in capacity, regulatory filings, or commercialization sustainably.
Low Net ProfitabilityDespite healthy gross margins, a net margin near zero and negative EBIT indicate operating expenses or SG&A and R&D are eroding returns. Prolonged low profitability reduces the firm's capacity to build reserves, fund long development cycles, or deliver shareholder returns absent structural cost improvement or higher-margin revenue mix.
Limited Scale & Operating ResourcesA small workforce (40 employees) constrains in-house capabilities across manufacturing scale-up, regulatory affairs, and global commercial operations—critical in medical devices and biomaterials. Scaling will likely require outsized hiring, partnerships, or acquisitions, increasing execution complexity and operational risk over months.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42p and its highest was 16.80p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £9.00M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 13, 2026 which is in 159 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jan 30, 2026. The company reported 0.008p earnings per share for the quarter, beating the consensus estimate of N/A by 0.008p.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of 0.008p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―
Options Prices
Currently, No data available
---